Ciclesonide (CAS 126544-47-6)
See product citations (2)
QUICK LINKS
Ciclesonide is a compound with applications in the study of anti-inflammatory processes. In research applications, it is often used to explore the mechanisms of action of glucocorticoids in the modulation of inflammatory pathways. The compound′s activation into its active metabolite by esterases in the target tissue is a focal point, as it provides insights into the localized effects of prodrugs. Studies involving ciclesonide may also examine its interaction with glucocorticoid receptors and the subsequent transrepression or transactivation of gene expression. This research is valuable in understanding the regulation of cytokine production and the inhibition of inflammatory mediator release. Additionally, ciclesonide serves as a model compound in the development of novel formulations and delivery systems aimed at improving the bioavailability and targeting of glucocorticoids.
Ciclesonide (CAS 126544-47-6) References
- Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. | Silvestri, M., et al. 2012. Immunol Lett. 141: 190-6. PMID: 22015638
- Efficacy of ciclesonide in the treatment of patients with asthma exacerbation. | Zietkowski, Z., et al. 2019. Postepy Dermatol Alergol. 36: 217-222. PMID: 31320857
- Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. | Mori, N., et al. 2021. J Microbiol Immunol Infect. 54: 109-112. PMID: 33054978
- The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. | Matsuyama, S., et al. 2020. J Virol. 95: PMID: 33055254
- The Antiasthma Medication Ciclesonide Suppresses Breast Cancer Stem Cells through Inhibition of the Glucocorticoid Receptor Signaling-Dependent YAP Pathway. | Kim, SL., et al. 2020. Molecules. 25: PMID: 33352739
- Inhaled ciclesonide is efficacious and well tolerated in the treatment of severe equine asthma in a large prospective European clinical trial. | Pirie, RS., et al. 2021. Equine Vet J. 53: 1094-1104. PMID: 33403727
- A review of Ciclesonide in COVID-19. Still a long way to go. | Deokar, K., et al. 2021. Adv Respir Med. 89: 79-81. PMID: 33471354
- Development of ciclesonide analogues that block SARS-CoV-2 RNA replication. | Tsuji, G., et al. 2021. Bioorg Med Chem Lett. 43: 128052. PMID: 33887440
- Ciclesonide activates glucocorticoid signaling in neonatal rat lung but does not trigger adverse effects in the cortex and cerebellum. | Jaumotte, JD., et al. 2021. Neurobiol Dis. 156: 105422. PMID: 34126164
- Ciclesonide Impacts Clinicopathological Features of Eosinophilic Esophagitis. | Nistel, M., et al. 2021. J Allergy Clin Immunol Pract. 9: 4069-4074. PMID: 34293498
- Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. | Song, JY., et al. 2021. J Clin Med. 10: PMID: 34441840
- Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis. | Syverson, EP. and Hait, E. 2022. Gastroenterol Hepatol (N Y). 18: 207-212. PMID: 35505944
- Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication. | Tsuji, G., et al. 2022. J Pharmacol Sci. 149: 81-84. PMID: 35641031
- Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial. | Terada, J., et al. 2022. EClinicalMedicine. 49: 101484. PMID: 35692220
- Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study. | Kuo, KC., et al. 2022. BMC Pulm Med. 22: 368. PMID: 36171597
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ciclesonide, 10 mg | sc-207432 | 10 mg | $205.00 |